Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$2.85 - $8.73 $68,277 - $209,144
-23,957 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$13.2 - $18.1 $316,232 - $433,621
23,957
23,957 $434,000

Others Institutions Holding ATRA

About Atara Biotherapeutics, Inc.


  • Ticker ATRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,362,304
  • Market Cap $1.08B
  • Description
  • Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
More about ATRA
Track This Portfolio

Track Virtus Fund Advisers, LLC Portfolio

Follow Virtus Fund Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtus Fund Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtus Fund Advisers, LLC with notifications on news.